RESEARCH PROGRAM

Heading at first‑in‑human‑trial

One of the two polypeptide hormones is lead development molecule with the other structurally and functionally slightly different peptide synthesized from the same bacterial precursor protein being back-up molecule

Following pharmacokinetics and initial dosing and safety studies of encapsulated recombinant lead molecule in humans with oral administration, a double blinded and placebo-controlled randomized, cross-over trial will be run for six months in cardio-metabolic at-risk individuals